Abstract
The term ‘mood stabilizer’ has been applied to a number of medications for the treatment of patients with bipolar disorder. The operational definition of the properties of a mood-stabilizing medication has varied according to the properties of specific medications and the clinical characteristics of the illness. Randomized controlled trials of agents accepted or proposed as mood stabilizers are reviewed to marshall the available evidence in support of this claim. In addition, potential pharmacological mechanisms underlying mood-stabilizing effects of established compounds are reviewed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Keck PE Jr, McElroy SL, Arnold LM . Bipolar disorder Med Clin NA 2001 85: 645–661
McElroy SL, Keck PE Jr, Strakowski SM . Mania, psychosis and antipsychotics J Clin Psychiatry 1996 57: 14–26
Keck PE Jr, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode Am J Psychiatry 1998 155: 646–652
Strakowski SM, Keck PE Jr, McElroy SL, West SA, Sax KW, Hawkins JM et al. Twelve-month outcome after a first hospitalization for affective psychosis Arch Gen Psychiatry 1998 55: 49–55
Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL . The enduring psychosocial consequences of mania and depression Am J Psychiatry 1993 150: 720–727
Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD . Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania Am J Psychiatry 1999 156: 1264–1266
Murray CJL, Lopez AD . The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 Harvard University Press: Cambridge, MA 1996
Strakowski SM, McElroy SL, Keck PE Jr, West SA . Suicidality among patients with mixed and manic bipolar disorder Am J Psychiatry 1996 153: 674–676
Dilsaver S, Chen Y-H, Swann AC, Shoaib AM, Krajewski KJ . Suicidality in patients with pure and depressive mania Am J Psychiatry 1994 151: 1312–1315
Keck PE Jr, McElroy SL . Bipolar disorders. In: Nathan PE, Gorman JA (eds). A Guide to Treatments That Work Oxford University Press: New York 1998
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision American Psychiatric Press: Washington, DC 2000
Keck PE Jr, McElroy SL, Kmetz G et al. Clinical features of mania in adulthood In: Shulman K, Tohen M, Kutcher S (eds) Mood Disorders Throughout the Life Span John Wiley & Sons, New York 1996 pp 265–279
Goodwin FK, Jamison KR . Manic-Depressive Illness Oxford University Press: New York 1990
McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI, Faedda GL, Swann AC . Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania Am J Psychiatry 1992 149: 1633–1644
Sach GS . Treatment-resistant bipolar depression Psychiatry Clin NA 1996 19: 215–236
Pope HG Jr, Lipsinki JF . Diagnosis in schizophrenia andmanic-depressive illness: a reassessment of the specificity of ‘schizophrenic’ symptoms in light of current research Arch Gen Psychiatry 1978 35: 811–828
Rothschild AJ . Management of psychotic, treatment-resistant depression Psychiatric Clin NA 1996 19: 237–252
Hopkins HS, Gelenberg AJ . Treatment of bipolar disorder How far have we come? Psychopharmacol Bull 1994 30: 27–37
Calabrese JR, Rapport DJ . Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder J Clin Psychiatry 1999 60 (Suppl 5): 5–13
Keck PE Jr, McElroy SL . Redefining mood stabilization J Affect Disord 2001 (in press)
Manji HK, Duman RS . Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapies Psychopharmacol Bull 2001 35: 5–49
Manji HK, Drevets WC, Charney DS . The cellular neurobiology of depression Nature Med 2001 7: 541–552
Dunner DL, Fieve RR . Clinical factors in lithium carbonate prophylaxis failure Arch Gen Psychiatry 1974 30: 229–233
Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J . Depression during mania: treatment response to lithium or divalproex Arch Gen Psychiatry 1997 54: 37–42
Keck PE Jr, McElroy SL . Treatment of bipolar disorder with lithium Psychiatr Ann 1993 23: 1–6
Keck PE Jr, McElroy SL, Strakowski SM . Anticonvulsants and antipsychotics in the treatment of bipolar disorder J Clin Psychiatry 1998 59 (Suppl 6): 74–82
Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study Arch Gen Psychiatry 2000 57: 841–849
Calabrese JR, Delucci GA . Spectrum of efficacy of valproate in 55 patients with rapid cycling bipolar disorder Am J Psychiatry 1990 147: 431–434
Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG et al. Olanzapine versus placebo in the treatment of acute mania Am J Psychiatry 1999 156: 702–709
Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI . Valproate in the treatment of acute mania. A placebo-controlled study Arch Gen Psychiatry 1991 48: 62–68
Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F . Efficacy of divalproex vs lithium and placebo in the treatment of mania JAMA 1994 271: 918–924
Tohen M, Zhang F, Feldman P et al. Olanzapine versus haloperidol treatment of acute mania. New Research Program and Abstracts of the American Psychiatric Association Annual Meeting, New Orleans, LA, 2001 p 105
Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK . Does olanzapine have antidepressant properties? A retrospective preliminary study Bipolar Disord 2000 2: 196–199
Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG et al. A novel augmentation strategy for treating resistant major depression Am J Psychiatry 2001 158: 131–134
Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassaf A, Petty F et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder Arch Gen Psychiatry 2000 57: 481–489
McElroy SL, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R et al. Olanzapine in treatment-resistant bipolar disorder J Affect Disord 1998 49: 119–122
Zarate CA Jr, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders J Clin Psychiatry 1998 59: 24–48
Keck PE Jr, McElroy SL, Nemeroff CB . Anticonvulsants in the treatment of bipolar disorder J Neuropsychiatry Clin Neurosci 1992 4: 395–405
Ballenger JL, Post RM . Therapeutic effects of carbamazepine in affective illness: a preliminary report Commun Psychopharmacol 1978 2: 159–175
Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S . Carbamazepine versus lithium in mania: a double-blind study J Clin Psychiatry 1987 48: 89–93
Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD et al. Carbamazepine compared with lithium in the treatment of mania Arch Gen Psychiatry 1991 48: 915–921
Grossi E, Sacchetti E, Vita A et al. Carbamazepine verus chlorpromazine in mania; a double-blind trial In: Emrich HM, Okuma T, Muller AA (eds) Anticonvulsants in Affective Disorders Excerpta Medica: Amsterdam, The Netherlands 1984 pp 177–187
Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study Psychopharmacology 1979 66: 211–217
Post RM, Uhde TW, Roy-Byrne PP, Joffe RT . Antidepressant effects of carbamazepine Am J Psychiatry 1986 143: 29–34
Small JG . Anticonvulsants in affective disorders Psychopharmacol Bull 1990 26: 25–36
Kramlinger KG, Post RM . The addition of lithium to carbamazepine Arch Gen Psychiatry 1989 46: 794–800
Placidi GF, Lenzi A, Lazzerini F . The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-bind 3-year trial in 83 patients J Clin Psychiatry 1986 47: 490–494
Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic depressive illness Psychopharmacology 1981 73: 95–96
Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomised study J Affect Disord 1997 43: 151–161
Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM . Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder J Clin Psychiatry 1997 58: 470–478
McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR et al. Clozapine in the treatment of psychotic mooddisorders, schizoaffective disorder, and schizophrenia J Clin Psychiatry 1991 52: 411–414
Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA et al. Clozapine for treatment-refractory mania Am J Psychiatry 1996 153: 759–764
Frye MA, Ketter TA, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics J Affect Disord 1998 48: 91–104
Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up J Clin Psychiatry 1994 55: 295–300
Barbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E . Response to clozapine in acute mania is more rapid than that of chlorpromazine Int Clin Psychopharmacol 1997 12: 109–112
Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ . Clinical outcome in randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and history of mania Am J Psychiatry 1999 156: 1164–1169
Ghaemi SN, Sach GS . Long-term risperidone treatment in bipolar disorder: 6-month follow-up Int Clin Psychopharmacol 1997 12: 333–338
Hillert A, Maier W, Wetzel H, Benkert O . Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome—a functional approach Pharmacopsychiatry 1992 25: 213–217
Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders J Clin Psychiatry 1995 56: 466–470
Segal J, Berk M, Brook S . Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial Clin Neuropharmacol 1998 21: 176–180
Sachs GS Risperidone Bipolar Study Group. Safety and efficacy of risperidone vs placebo as add-on therapy to mood stabilizers in the treatment of manic phase of bipolar disorder. Presented at the 38th Annual Meeting of the ACNP, Acapulco, Mexico, December 1999
Keck PE Jr, Ice K . A three-week double-blind, randomized trial of ziprasidone in placebo as add-on therapy to mood stabilizers in the treatment of manic phase of bipolar disorder. Presented at the 38th Annual Meeting of the ACNP, Acapulco, Mexico, December 1999
Keck PE Jr, Reeves KR, Harrigan EP . A double-bind, placebo-controlled study of ziprasidone in the acute treatment of patients with schizoaffective disorder J Clin Psychopharmacol 2001 21: 27–35
Ghaemi SN, Katzow JJ . The use of quetiapine for treatment-resistant bipolar disorder: a case series Ann Clin Psychiatry 1999 11: 137–140
Keck PE Jr . New antiepileptics and atypical antipsychotics in the treatment of bipolar disorder. Clinical issues in bipolar disorder: Data from the Stanley Foundation Bipolar Network Scientific Program of the American Psychiatric Association Annual Meeting, New Orleans, LA 2001
Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G . Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy Bipolar Disord 2000 2: 249–255
Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders J Clin Psychopharmacol 2000 20: 607–614
Anand A, Oren DA, Berman RM et al. Lamotrigine treatment of lithium failure outpatient mania: a double-blind, placebo-controlled trial. Abstracts of the 3rd International Conference on Bipolar Disorder, Pittsburgh, PA. Munksgaard: Copenhagen, Denmark 1999 p 23
Ichim L, Berk M, Brook S . Lamotrigine compared with lithium in mania: a double-blind, randomized controlled trial Ann Clin Psychiatry 2000 12: 5–10
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD . A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression J Clin Psychiatry 1999 60: 79–88
Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder J Clin Psychiatry 2000 61: 841–850
Muller AA, Stoll K-D . Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany In: Emrich HM, Okuma T, Muller AA (eds) Anticonvulsants in Affective Disorders Excerpta Medica: Amsterdam, The Netherlands 1984 pp 134–147
Emrich HM . Studies with oxcarbazepine (Trileptalin acute®) mania Int Clin Psychopharmacol 1990 5 (Suppl): 83–88
Cabrera JF, Muhlbauer HD, Schley J et al. Long-term randomized clinical trial on oxcarbazepine vs lithium in bipolar and schizoaffective disorders: preliminary results Pharmacopsychiatry 1986 19: 282–283
Wildgrube C . Case studies on prophylactic long-term effects of oxcarbazepine in recurrent affective disorders Int Clin Psychopharmacol 1990 5 (Suppl): 89–94
Calabrese JR . Topiramate versus placebo in the treatment of acute mania. Presented at the European College of Neuropsychopharmacology Meeting. London, UK: September 2000
Blackshear MA, Sanders-Bush E . Serotonin receptor sensitivity after acute and chronic treatment with mianserin J Pharmacol Exp Ther 1982 221: 303–308
Keck PE Jr, McElroy SL, Strakowski SM, West SA . Pharmacologic treatment of schizoaffective disorder Psychopharmacology 1994 114: 529–538
Vaidya VA, Duman RS . Role of 5HT2 receptors in down-regulation of BDNF by stress Neurosci Letts 1999 287: 1–4
Anand A, Charney D . Abnormalities in catecholamines and pathophysiology of bipolar disorder In: Soares JC, Gershon S (eds) Bipolar Disorders. Basic Mechanisms and Therapeutic Implications Marcel Dekker: New York 2000 pp 59–94
Janowsky DS, Overstreet DH . Cholinergic dysfunction in mood disorders In: Soares JC, Gershon S (eds) Bipolar Disorders, Basic Mechanisms and Therapeutic Implications Marcel Dekker: New York 2000 pp 95–120
Oquendo MA, Mann JJ . Serotonergic dysfunction in mood disorders In: Soares JC, Gershon S (eds) Bipolar Disorders. Basic Mechanisms and Therapeutic Implications Marcel Dekker: New York 2000 pp 121–142
Massat I, Souery D, Mendelewicz J et al. The GABAergic hypothesis of mood disorders In: Soares JC, Gershon S (eds) Bipolar Disorders. Basic Mechanisms and Therapeutic Implications Marcel Dekker: New York 2000 pp 143–166
Hokin LE, Dixon JF, Los GV . Acute inhibition but chronic upregulation and stabilization of glutamate uptake in synaptosomes by lithium In: Manji HK, Bowden CL, Belmaker RH (eds) Bipolar Medications: Mechanisms of Action American Psychiatric Press: Washington, DC 2000 pp 65–86
Post RM, Weiss SRB, Clark M et al. Lithium, carbamazepine, and valproate in affective illness: biochemical and neurobiological mechanisms In: Manji HK, Bowden CL, Belmaker RH (eds) Bipolar Medications: Mechanisms of Action American Psychiatric Press: Washington, DC 2000 pp 219–248
Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P . BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization Nature 2001 411: 86–89
Richtand N, Woods SC, Berger SP et al. D3 dopamine receptor, behavioral sensitization, psychosis Neurosci Biobehav Rev 2001 25: 427–443
Chen G, Huang LD, Zeng WZ, K Manji H . Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability Int J Neuropsychopharmacol 2001 4: 47–64
Tohen M, Jacobs TG, Meyers TM et al. Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder. New Research Program and Abstracts of the American Psychiatric Association Annual Meeting, Chicago, IL 2000 p 160
Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder J Clin Psychiatry 1997 58: 95–99
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keck Jr, P., McElroy, S., Richtand, N. et al. What makes a drug a primary mood stabilizer?. Mol Psychiatry 7 (Suppl 1), S8–S14 (2002). https://doi.org/10.1038/sj.mp.4001013
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4001013